Vcare 2024 Annual Review
Published Time:
2025-01-27 18:01
Source:
I. Innovative Drug R&D Has Witnessed Multiple Significant Advances
① Vicagrel Capsules (anti-platelet):
China: Preparing NDA submission
US: IND approved by FDA
② VC005 Tablets (next-gen selective JAK1 inhibitor):
Phase III for moderate-severe atopic dermatitis: 1st patient enrolled
Phase III for ankylosing spondylitis: Initiated
③ VC005 Gel (topical JAK1 inhibitor):
Phase II for mild-moderate atopic dermatitis: Initiated
II. Patent Layout for Innovative Drugs
Filed 10 patent applications; Granted 7 patents.
III. Sustained Revenue Growth
2024 revenue: ~RMB 440 million; Contract value: ~RMB 690 million.
IV. Strategic Corporate Development
① Closed Series C+ financing (~RMB 200M); Completed shareholding reform.
② Commenced photovoltaic power project construction.
③ Completed warehouse expansion & lab renovation.
④ Tianshu Pharmaceutical Phase I facility passed final acceptance.
V. Accelerated Group Digitalization
① Completed Phase II: CRM platform & data middleware established.
② Launching Phase III: R&D & production project management systems.
VI. Employee Care Highlights
① Organized 8 cultural events
② Held 12 Happy Hour activities
③ Completed 115 promotions
④ ~70 employees received equity incentives
⑤ Conducted 400+ internal trainings
⑥ Hosted 10+ external expert lectures
VII. Honors & Qualifications
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; Jiangsu Provincial Three-Star Cloud-Adopted Enterprise; Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry
Related News
27
2017
/
03
Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare
The delegation of Political Consultative Conference of Wenzhou Ouhai District, accompanied by vice chairman of Political Consultative Conference of Pukou Economic Development Zone visited Jiangsu Vcare Pharmaceutical Technology Co., Ltd. on the afternoon of March 27, 2017. Yongqiang Liu, the general manager of Jiangsu Vcare received the delegation. Mr. Liu introduced the company's development history and R&D progress. He focused on the progress of phase II clinical trials and the future market prospect of innovative drug Vicagrel. The delegation highly recognized Vcare's advanced equipment and facilities, harmonious human environment and comprehensive research and development capabilities.
View Details
14
2017
/
03
Jiangsu Vcare Held “Firefighting and First Aid” Training
Jiangsu Vcare invited Lei Wang, a special instructor of Nanjing Anqu Fire Education Center to give a “Firefighting and First Aid” course to new employees on March 14, 2017 and 26 new employees participated in the training. Mr. Wang collected a large number of fire cases and carefully analyzed the causes of these fires. He taught everyone how to deal with fires. His explanations made everyone fully aware of the importance and urgency of fire safety. At the same time, everyone had a better understanding of various fire extinguishers and their instructions.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn